Avanir Pharmaceuticals competitors

Dr. Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012. Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School of Medicine and his Bachelor of Arts in molecular biology and biochemistry from Wesleyan University.

Remy is the CEO of Minerva Neurosciences (Nasdaq: NERV) and was formerly an advisor to Index Ventures, Chief Medical Officer of the Index Life VI biotech fund raised by Index Ventures in 2012, and a member of the Scientific Advisory Board of the fund.

Adrienne Giannone is a President and CEO at EDGE ELECTRONICS INC and Board Member at LISTnet - Long Island Software & Technology Network and is based in Headquartered in Bohemia, Li, New York. She has worked as Sales at ERA, In. Adrienne attended Martin Van Buren School.

Anders Hedegaard is a Chief Executive Officer at Rodenstock and is based in München, Free State of Bavaria, Germany.

Dr. Hong co-founded Brii Bio in 2018 and has served as Chief Executive Officer since the company’s inception. Prior to starting Brii Bio, Dr. Hong was Senior Vice President and Head of GlaxoSmithKline's (GSK) Infectious Diseases Therapy Area Unit. He was widely credited as the key architect of GSK's comeback and success in HIV and Infectious Diseases medicine discovery and development. Under his leadership, ViiV Healthcare’s (a joint venture between GSK, Pfizer, and Shionogi) HIV business was revitalized with the approval of Tivicay and Triumeq. Dr. Hong was the champion of GSK's effort in long-acting HIV treatment and prevention therapies resulting in the first approval of Cabenuva. Dr. Hong is a public health advocate who has helped establish multiple public-private partnerships with the U.S./E.U. governments (DTRA, BARDA, NIH & IMI) and philanthropic organizations (Gates Foundation & Wellcome Trust). He helped to create GSK's Institute for Infectious Diseases and Public Health in Beijing, China. Dr. Hong started Ardea Biosciences (later acquired by AstraZeneca). He also held leadership positions at Valeant Pharmaceuticals and Schering-Plough Research Institute (now Merck). Dr. Hong has more than 25 years of experience in drug discovery and development and has brought more than 40 compounds into development, including many that have been approved and launched. He has served as a board member of Anacor Pharmaceuticals (acquired by Pfizer) and ViiV Healthcare, and also chaired the board of Qura Therapeutics.